TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
OCUL

Ocular Therapeutix Inc

Healthcare · Biotechnology

10.10$ +2.7% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Ocular Therapeutix Inc (OCUL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 84.1% of the shares are freely tradable; institutional investors hold 95.7%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 95.7%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.9%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 84.1%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 15.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 220Mio.

Largest Shareholders

Institutions

Institutions OCUL
Name Stake (%) Shares Change (%) Date
FMR Inc 14.87 32,653,764 +2.7 03/31/2026
Deep Track Capital, LP 8.96 19,686,282 +0.0 06/30/2026
BlackRock Inc 7.35 16,132,931 +3.4 03/31/2026
venBio Select Advisor LLC 5.61 12,315,000 +14.3 03/31/2026
SUMMER ROAD LLC 5.56 12,208,296 +2.8 06/30/2026
VR Adviser, LLC 4.71 10,346,926 +41.4 03/31/2026
Vanguard Capital Management, LLC 3.97 8,719,039 +0.0 03/31/2026

Funds

Funds OCUL
Name Stake (%) Shares Change (%) Date
Fidelity Growth Compy Commingled Pl S 5.98 13,134,074 +0.0 07/31/2026
Fidelity Growth Company Fund 4.42 9,704,363 +0.0 07/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 3.03 6,651,082 +0.5 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings OCUL
Person Role Shares Value As of Type
Dugel Pravin See Remarks 3,270,332 33,030,353 $ Aug 24, 2026 both
Notman Donald Chief Operating Officer 366,529 3,701,943 $ Aug 31, 2026 direct
Nayak Sanjay Chief Strategy Officer 326,898 3,301,670 $ Aug 24, 2026 direct
Heier Jeffrey S. Chief Scientific Officer 318,326 3,215,093 $ Aug 24, 2026 direct
Kaiser Peter Chief Development Officer 264,378 2,670,218 $ Aug 24, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Aug 31, 2026 Notman Donald Chief Operating Officer Sell 1,099 10.24 11,254
Aug 25, 2026 Dugel Pravin See Remarks Other 50,092 0.00
Aug 24, 2026 Kaiser Peter Chief Development Officer Sell 3,035 10.77 32,687
Aug 24, 2026 Nayak Sanjay Chief Strategy Officer Sell 1,897 10.78 20,450
Aug 24, 2026 Heier Jeffrey S. Chief Scientific Officer Sell 3,296 10.78 35,531
Aug 24, 2026 Dugel Pravin See Remarks Sell 21,649 10.77 233,160

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?